# US 2026/0241050 A1 · Reagents and methods for imaging cancers expressing pdgfralpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0241050 A1
- Document ID: US20260241050A1
- Status: Published application
- Kind: A1
- Application number: 19/472,083
- Filed: 2024-04-04
- Published: 2026-08-20
- Earliest claimed: 2023-04-04
- Assignees: Telix Pharmaceuticals (Innovations) Pty Ltd.; Eli Lilly and Company
- Applicants: Telix Pharmaceuticals (Innovations) Pty Ltd.; Eli Lilly and Company
- Inventors: Michael Paul Wheatcroft; Alesia Ivashkevich; Corinne Letendre; Rodney John Hicks; Tracey Jean Brown; Neel Jagdish Patel; Angela Man Yin Hong
- Web page: https://patentgrep.com/patent/US20260241050A1

## CPC

- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/103: {against receptors for growth factors or receptors for growth regulators}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2121/00: Preparations for use in therapy
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFRalpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.

## Claims

### Claim 1

An olaratumab antibody or olaratumab antibody bioconjugate, suitable for radiolabelling with a diagnostic radioisotope.

### Claim 2 (depends on 1)

The olaratumab bioconjugate of claim 1, wherein the bioconjugate comprises an olaratumab antibody conjugated to a chelating or linker group selected from: TMT (6,6″-bis[N,N″,N′″-tetra(carboxymethyl)aminomethyl)-4′-(3-amino-4-methoxyphenyl)-2,2′:6′,2″-terpyridine), DOTA (1,4,7,10-tetraazacyclododecane-NN′,N″(N′″-tetraacetic acid), TCMC, DO3A, CB-DO2A, NOTA, Diamsar, DTPA, CHX-A″-DTPA, olaratumab-TETE, Te2A, HBED, DFO, DFOsq, DFO-NCS and HOPO.

### Claim 3

An olaratumab antibody or antigen binding fragment thereof, conjugated to a radioisotope suitable for in vivo imaging, for:
the detection or imaging of PDGFRalpha-expressing tumours in a subject;
for the diagnosis of a PDGFRalpha-expressing cancer in a subject;
for producing an image of a PDGFRalpha-expressing cancer in a subject;
for classifying a cancer as sensitive to treatment with a PDGFRalpha-inhibitor;
for classifying or selecting a patient for eligibility for cancer therapy with an inhibitor of PDGFRalpha; or
for monitoring the response to treatment of a PDGFRalpha-expressing cancer or a subject having a PDGFRalpha-expressing cancer.

### Claim 4 (depends on 1, 2, 3)

The olaratumab antibody or antigen binding fragment thereof, or antibody bioconjugate of any one of claims 1 to 3, comprising an antigen binding domain that competitively inhibits the binding of an antibody comprising a VH comprising a sequence as set forth in SEQ ID NO: 4 and a VL comprising a sequence as set forth in SEQ ID NO: 12.

### Claim 5 (depends on 1, 2, 3, 4)

The olaratumab antibody or antigen binding fragment thereof or bioconjugate of any one of claims 1 to 4, wherein the antibody or fragment thereof comprises an HCDR1, a HCDR2 and an HCDR3 of an antigen binding domain having a variable heavy chain as defined in in SEQ ID NO: 4 and a LCDR1, LCDR2 and LCDR3 of an antigen binding domain having a VL as defined in SEQ ID NO: 12.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 5, wherein the antibody or antigen binding fragment comprises an antigen binding domain comprising:
(i) a VH comprising a complementarity determining region (CDR) 1 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 1, a CDR2 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set in SEQ ID NO: 2, and a CDR3 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 3;
(ii) a VH comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 4;
(iii) a VL comprising a CDR1 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 9, a CDR2 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 10 and a CDR3 comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 11;
(iv) a VL comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 12;
(v) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 1, a CDR2 comprising a sequence set forth in SEQ ID NO: 2 and a CDR3 comprising a sequence set forth in SEQ ID NO: 3;
(vi) a VH comprising a sequence set forth in SEQ ID NO: 4;
(vii) a VL comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 9, a CDR2 comprising a sequence set forth in SEQ ID NO: 10 and a CDR3 comprising a sequence set forth in SEQ ID NO: 11;
(viii) a VL comprising a sequence set forth in SEQ ID NO: 12;
(ix) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 1, a CDR2 comprising a sequence set forth between in SEQ ID NO: 2, and a CDR3 comprising a sequence set forth in SEQ ID NO: 3; and a VL comprising a CDR1 comprising a sequence set SEQ ID NO: 9, a CDR2 comprising a sequence set forth in SEQ ID NO: 10, and a CDR3 comprising a sequence set forth in SEQ ID NO: 11; or
(x) a VH comprising a sequence set forth in SEQ ID NO: 4, and a VL comprising a sequence set forth in SEQ ID NO: 12.

### Claim 7 (depends on 6)

The olaratumab antibody or antigen binding fragment thereof of claim 6, further comprising:
(i) a VH comprising a framework region (FR) 1 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 5; a FR2 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 6; a FR3 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 7; a FR4 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 8; and
(ii) a VL comprising a framework region (FR) 1 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 13; a FR2 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 14; a FR3 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 15; a FR4 comprising or consisting of a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% identical to a sequence as set forth in SEQ ID NO: 16.

### Claim 8 (depends on 6)

The olaratumab antibody or antigen binding fragment thereof of claim 6, further comprising:
(i) a VH comprising a framework region (FR) 1 comprising or consisting of a sequence as set forth in SEQ ID NO: 5; a FR2 comprising or consisting of a sequence as set forth in SEQ ID NO: 6; a FR3 comprising or consisting of a sequence as set forth in SEQ ID NO: 7; a FR4 comprising or consisting of a sequence as set forth in SEQ ID NO: 8, and
(ii) a VL comprising a framework region (FR) 1 comprising or consisting of a sequence as set forth in SEQ ID NO: 13; a FR2 comprising or consisting of a sequence as set forth in SEQ ID NO: 14; a FR3 comprising or consisting of a sequence as set forth in SEQ ID NO: 15; a FR4 comprising or consisting of a sequence as set forth in SEQ ID NO: 16.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 8, wherein the antibody or antigen binding fragment thereof comprises a VH comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 4; and/or a VL comprising a sequence at least about 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence set forth in SEQ ID NO: 12; wherein the sequence variation between the VH and VL and the sequence of SEQ ID NO: 4 and 12 is not in the CDRs and wherein the antibody or antigen binding fragment thereof retains the ability to bind to PDGFRalpha.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 9, wherein the antibody or antigen binding fragment thereof comprises a VH and/or a VL comprising no more than 1, no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19 or no more than 20 amino acid residue substitutions, deletions or additions, compared to the amino acid sequences as set forth in SEQ ID NO: 4 or 12, respectively; wherein the amino acid substitutions, deletions or additions are not in the CDRs and the antibody or antigen binding fragment thereof retains the ability to bind to PDGFRalpha.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 10, wherein the antibody or antigen binding fragment is in the form of:
(i) a single domain antibody (sdAb);
(ii) a single chain Fv fragment (scFv);
(iii) a dimeric scFv (di-scFv); or
(iv) one of (ii) or (iii) linked to a constant region of an antibody, Fc or a heavy chain constant domain (CH) 2 and/or CH3.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 10, wherein the antibody or antigen binding fragment is in the form of:
(i) a diabody;
(ii) a triabody;
(iii) a tetrabody;
(iv) a Fab;
(v) a F(ab′)2;
(vi) a Fv;
(vii) a bispecific antibody or other form of multispecific antibody; or
(viii) one of (i) to (vii) linked to a constant region of an antibody, Fc or a heavy chain constant domain (CH) 2 and/or CH3.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 12, wherein the antibody or antigen binding fragment is in the form of an immunoglobulin such as an IgG1, IgG2, IgG3 or IgG4.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 13, wherein the olaratumab antibody comprises a heavy chain constant region as defined in SEQ ID NO: 17 and/or a light chain constant region as defined in SEQ ID NO: 18.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 1 to 14, wherein the olaratumab antibody comprises a heavy chain as set forth in SEQ ID NO: 19 and/or a light chain as set forth in SEQ ID NO: 20.

### Claim 16 (depends on 13, 14, 15)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 15, wherein the antibody or antigen binding fragment thereof comprises one or more amino acid substitutions in the constant region, so as to reduce the in vivo half-life of the antibody.

### Claim 17 (depends on 13, 14, 15, 16)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 16, wherein the antibody or antigen binding fragment thereof comprises substitutions at one or more of residues His310, His435, Tyr436 and Ile253 of the constant region of the antibody (Kabat EU index numbering).

### Claim 18 (depends on 13, 14, 15, 16, 17)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 17 wherein the antibody or antigen binding fragment thereof comprises an amino acid substitution at position 310 selected from alanine, glutamic acid or glutamine (Kabat EU index numbering).

### Claim 19 (depends on 13, 14, 15, 16, 17, 18)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 18, wherein the antibody or antigen binding fragment thereof comprises an amino acid substitution at position 435 selected from arginine, glutamine or alanine (Kabat EU index numbering).

### Claim 20 (depends on 13, 14, 15, 16, 17, 18, 19)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 19, wherein the antibody or antigen binding fragment thereof comprises an alanine residue at position 310 and glutamine residue at position 435 (Kabat EU index numbering).

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 13 to 19, wherein the antibody or antigen binding protein thereof comprises an amino acid substitution at position Ser228 and/or Leu235, preferably wherein the substitution is Leu235Glu and/or Ser228Pro.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 16 to 21, wherein the binding affinity for FcRn and/or the serum half-life of the antibody or antigen binding fragment thereof is decreased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or 100-fold; or wherein the binding affinity for FcRn and/or the serum half-life of said modified antibody is reduced by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%, compared to an immunoglobulin that does not comprise the same substitutions.

### Claim 23 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 12, wherein the antibody or antigen binding fragment thereof comprises a radioisotope suitable for in vivo imaging methods for detection of tumour or cancer masses.

### Claim 24 (depends on 23)

The olaratumab antibody or antigen binding fragment thereof of claim 23, wherein the radioisotope is selected from: fluorine-18 (18F), gallium-67 and gallium-68 (67Ga and 68Ga), indium-111 (111In), iodine-123 and iodine-124, technetium-99 (99mTc), terbium-155 and terbium-159 (155Tb and 159Tb) and zirconium-89 (89Zr).

### Claim 25 (depends on 23, 24)

The olaratumab antibody or antigen binding fragment thereof of any one of claims 23 to 24, wherein the radioisotope is conjugated to the antibody or antigen binding fragment thereof directly e.g. by halogenation of amino acid residues.

### Claim 26 (depends on 23, 24)

The olaratumab or antigen binding fragment thereof of any one of claims 23 to 24, wherein the radioisotope is linked indirectly to the antibody or antigen binding fragment thereof, for example via a chelator or other linking moiety.

### Claim 27 (depends on 26)

The olaratumab of claim 26, wherein the antibody or antigen binding fragment thereof is conjugated to a chelating moiety, selected from the group consisting of: TMT (6,6″-bis[N,N″,N′″-tetra(carboxymethyl)aminomethyl)-4′-(3-amino-4-methoxyphenyl)-2,2′:6′,2″-terpyridine), DOTA (1, 4,7,10-tetraazacyclododecane-NN′,N″(N′″-tetraacetic acid), TCMC, DO3A, CB-DO2A, NOTA, Diamsar, DTPA, CHX-A″-DTPA, TETE, Te2A, HBED, DFO, DFOsq, DFO-NCS and HOPO or other chelating agent known to the skilled person.

### Claim 28 (depends on 27)

The olaratumab of claim 27, wherein the radiolabelled olaratumab is 89Zr-olaratumab or a 89Zr labelled olaratumab, wherein the 89Zr is conjugated to the olaratumab via a linker, such as 89Zr-DFO-olaratumab, 89Zr-DFO-NCS-olaratumab, or 89Zr-DFO-Sq-olaratumab.

### Claim 29 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for in vivo imaging or detection of a PDGFRalpha-expressing cancer in a subject, wherein the method comprises:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
thereby imaging or detecting the cancer in the subject.

### Claim 30 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for the diagnosis of a PDGFRalpha-expressing cancer in a subject, where the method comprises:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
determining the presence or absence of the antibody or antigen binding fragment thereof in the subject,
thereby diagnosing the cancer in the subject.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the detection of the antibody or fragment, or the presence or absence of the antibody or fragment is compared to a background or standard level to determine the presence of the cancer, thereby imaging or detecting or diagnosing the cancer in the subject.

### Claim 32 (depends on 29, 30)

The method of claim 29 or 30, wherein the detection or the presence or absence is compared to a model of disease classification or disease progression that is derived from data from one or more individuals, thereby imaging or detecting or diagnosing the cancer in the subject.

### Claim 33 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for producing an image of a PDGFRalpha-expressing cancer in a subject, the method comprising:
administering to a subject suspected of having the cancer, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
thereby producing an image of the cancer.

### Claim 34 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for producing an image of a PDGFRalpha-expressing cancer, the method comprising:
infusing an effective amount of a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof,
thereby producing an image of the cancer.

### Claim 35 (depends on 33, 34)

The method of claim 33 or 34, wherein the image of the cancer produced is used to generate training data for development of a model of disease progression or disease classification, optionally wherein the model is a machine learning model based on neural networks.

### Claim 36 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for classifying a cancer as sensitive to treatment with an inhibitor of PDGFRalpha, the method comprises:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
whereby the cancer is classified as sensitive to treatment with an inhibitor of PDGFRalpha when detection of the antibody or fragment thereof is below or the same as a background or threshold level; or
whereby the cancer is classified as not being sensitive to treatment with an inhibitor of PDGFRalpha when detection of the antibody or fragment thereof is above a background or threshold level.

### Claim 37 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for classifying a cancer as sensitive to treatment with an inhibitor of PDGFRalpha, the method comprises:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
whereby the cancer is classified as sensitive to treatment with an inhibitor of PDGFRalpha based on the output of a deep learning algorithm, indicating the presence of PDGFRalpha expressing cancer cells in the subject,
whereby the cancer is not classified as sensitive to treatment with an inhibitor of PDGFRalpha based on the output of a deep learning algorithm, indicating the absence of PDGFRalpha expressing cancer cells in the subject.

### Claim 38 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for classifying or selecting a patient for eligibility for cancer therapy with an inhibitor of PDGFRalpha, the method comprising:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
whereby the patient is classified/selected for cancer therapy with an inhibitor of PDGFRalpha when detection of the antibody or fragment thereof is above a background or standard level;
whereby the patient is not classified/selected for cancer therapy with an inhibitor of PDGFRalpha when detection of the antibody or fragment thereof is the same or below a background or standard level.

### Claim 39 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for classifying or selecting a patient for eligibility for cancer therapy with an inhibitor of PDGFRalpha, the method comprising:
administering to a subject in need thereof, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
whereby the patient is classified/selected for cancer therapy with an inhibitor of PDGFRalpha based on the output of a deep learning algorithm, indicating the presence of PDGFRalpha expressing cancer cells in the subject,
whereby the patient is not classified/selected for cancer therapy with an inhibitor of PDGFRalpha based on the output of a deep learning algorithm, indicating the absence of PDGFRalpha expressing cancer cells in the subject.

### Claim 40 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for determining the response to treatment of a PDGFRalpha-expressing cancer or a subject having a PDGFRalpha-expressing cancer, the method comprising:
administering to a subject who has received or is receiving a treatment for a PDGFRalpha-expressing cancer, a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28,
detecting the antibody or antigen binding fragment thereof in the subject,
comparing the amount of antibody or antigen binding fragment thereof detected in the subject compared to a reference amount of the antibody or antigen binding fragment thereof detected in the subject prior to the treatment,
determining that the cancer has responded to the treatment when the amount of the antibody or antigen binding fragment thereof detected is lower than the reference amount,
determining that the cancer has not responded to the treatment when the amount of the antibody or antigen binding fragment thereof is the same or higher than the reference amount,
thereby determining the response to treatment of a PDGFRalpha-expressing cancer or a subject having a PDGFRalpha-expressing cancer.

### Claim 41 (depends on 40)

The method of claim 40, wherein the treatment received or being received by the subject is selected from: surgery, chemotherapy, immunotherapy (such as CAR-T therapy), radiotherapy (including external beam radiation or immuno-radiotherapy) an inhibitor of PDGFRalpha and/or combinations thereof.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 41)

The method of any one of claims 33 to 39 or 41, wherein the inhibitor of PDGFRalpha is an olaratumab antibody, or functional antigen binding fragment thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the olaratumab antibody comprises a heavy variable chain as defined in SEQ ID NO: 4 and a light variable chain as defined in SEQ ID NO: 12.

### Claim 44 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

Use of a radiolabelled-olaratumab antibody or antigen binding fragment thereof, preferably an olaratumab antibody or antigen binding fragment thereof of any one of claims 3 to 28, in the manufacture of a medicament for:
in vivo imaging or detection of a PDGFRalpha-expressing cancer;
diagnosis of a PDGFRalpha-expressing cancer;
producing an image of a PDGFRalpha-expressing cancer;
classifying a cancer as sensitive to treatment with an inhibitor of PDGFRalpha; or
classifying or selecting a patient for eligibility for cancer therapy with an inhibitor of PDGFRalpha.

### Claim 45 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 29 to 43, wherein the method comprises allowing the radiolabelled-olaratumab antibody or antigen binding fragment thereof to concentrate at sites and/or tissues in said subject where the PDGFRalpha antigen is found in the subject, prior to the step of detecting.

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 29 to 43, wherein detection of the radiolabelled-olaratumab antibody or antigen binding fragment thereof comprises Positron Emission Tomography (PET), SPECT imaging or combinations thereof.

### Claim 47 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 29 to 43, or the use of claim 44, wherein a subject in need thereof is a subject that is suspected of having or is considered at risk of having a PDGFRalpha-expressing cancer.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 29 to 43, or the use of claim 44, wherein the cancer that is detected, imaged, diagnosed, classified or selected is selected from the group consisting of: soft tissue sarcoma (STS), chondrosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma, and rhabdomyosarcoma.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 29 to 43, or the use of claim 44, wherein the cancer that is detected, imaged, diagnosed, classified or selected is selected from the group consisting of: gastrointestinal stromal tumour (GIST), non-small cell lung cancer (NSCLC), pancreatic cancer, hepatocellular carcinoma, breast cancer, neuroendocrine tumours, ovarian cancer, cervical cancer, uterine cancer (such as adenosquamous carcinoma of the uterine cervix), colorectal cancer, gastric cancer, salivary gland cancer, biliary cancer, glioma, prostate cancer and renal cell carcinoma.
